The content on this site is intended for healthcare professionals only
Dr Paul de Souza from New South Wales, Australia, argues in favour of chemotherapy remaining as the standard treatment for symptomatic mCRPC in the era of novel agents. He explains that the various molecular states of prostate cancer cells, as well as the variety of molecular targets and mechanisms at play, together with the various genetic mutations, mean that not all cells will respond to androgen receptor blockade. Dr de Souza shows how the evidence for chemotherapy (eg, docetaxel, cabazitaxel) supports its continued use in mCRPC.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
